Loading
Latest filing published 17 Mar 2026 for Oncopeptides AB, €20k.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Eva Sabina Marianne Nordström, listed as senior executive, appears in our data through filings on Oncopeptides AB shares, published by Finansinspektionen. In total, 7 filings cover trades dated from 2 August 2018 to 16 March 2026.
In open-market terms, that means 2 purchases worth €1,934 on one side and 4 sales worth €992k on the other. Netting one side against the other leaves €990k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The newest entry dates from 17 March 2026: a transaction of €20k, in Oncopeptides AB. The last insider purchase was made public on 24 November 2020, 2,161 days ago. The median gap between a trade and its publication by Finansinspektionen is 1 day. The regulation allows three business days to notify a trade (MAR article 19). A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations